Inhibikase Therapeutics, Inc. SBIR Phase II Award, September 2017
A SBIR Phase II contract was awarded to Inhibikase Therapeutics in September, 2017 for $3,108,583.0 USD from the U.S. Department of Health & Human Services.
Name
# Contributions
Last Contribution
Find more entities like Inhibikase Therapeutics, Inc. SBIR Phase II Award, September 2017
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.